- Home
- MYTE vs ENGN Comparison
MYTE vs ENGN Comparison
Compare MYTE & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYTE
- ENGN
- Stock Information
- Founded
- MYTE 2006
- ENGN 1999
- Country
- MYTE Germany
- ENGN Canada
- Employees
- MYTE N/A
- ENGN N/A
- Industry
- MYTE Catalog/Specialty Distribution
- ENGN
- Sector
- MYTE Consumer Discretionary
- ENGN
- Exchange
- MYTE Nasdaq
- ENGN Nasdaq
- Market Cap
- MYTE 327.4M
- ENGN 293.1M
- IPO Year
- MYTE 2021
- ENGN N/A
- Fundamental
- Price
- MYTE $7.25
- ENGN $6.06
- Analyst Decision
- MYTE Buy
- ENGN Strong Buy
- Analyst Count
- MYTE 2
- ENGN 8
- Target Price
- MYTE $4.88
- ENGN $30.38
- AVG Volume (30 Days)
- MYTE 224.6K
- ENGN 193.4K
- Earning Date
- MYTE 11-19-2024
- ENGN 01-27-2025
- Dividend Yield
- MYTE N/A
- ENGN N/A
- EPS Growth
- MYTE N/A
- ENGN N/A
- EPS
- MYTE N/A
- ENGN N/A
- Revenue
- MYTE $953,698,416.00
- ENGN N/A
- Revenue This Year
- MYTE $10.88
- ENGN N/A
- Revenue Next Year
- MYTE $9.72
- ENGN N/A
- P/E Ratio
- MYTE N/A
- ENGN N/A
- Revenue Growth
- MYTE 9.97
- ENGN N/A
- 52 Week Low
- MYTE $2.41
- ENGN $4.42
- 52 Week High
- MYTE $8.24
- ENGN $18.40
- Technical
- Relative Strength Index (RSI)
- MYTE 69.44
- ENGN 27.67
- Support Level
- MYTE $7.01
- ENGN $5.75
- Resistance Level
- MYTE $7.89
- ENGN $6.55
- Average True Range (ATR)
- MYTE 0.42
- ENGN 0.68
- MACD
- MYTE 0.10
- ENGN -0.26
- Stochastic Oscillator
- MYTE 88.79
- ENGN 6.49
About MYTE MYT Netherlands Parent B.V. each representing one
MYT Netherlands Parent BV is a luxury e-commerce platform. The company offers luxury fashion wear for men, women, and kids. Also, the company sells shoes, bags, and accessories. The company operates in two segments which include the online segment and Retail store segments in which the majority of its revenue is generated from the Online segment.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.